The utility of the G2M pathway score as a biomarker to predict pCR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer is significantly hindered by the fact that it did not correlate with DFS of patients who underwent neoadjuvant chemotherapy in this study. Here, ERBB2 is linked to breast carcinoma.